Tyrosine kinase inhibitors, pancreatic hyperenzymemia and acute pancreatitis: A review

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 5, Issue 2, 2011, Pages 165-168

  Pezzilli, Raffaele ^a   Fabbri, Dario ^a   Imbrogno, Andrea ^a   Corinaldesi, Roberto ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

4 Amino 5 (4 methylphenyl) 7 (tert butyl)pyrazolo(3,4 d)pyrimidine; Amylases; Clinical trials; Controlled clinical trial; Drug toxicity; Lipase; Pancreatitis

Indexed keywords

ANTINEOPLASTIC AGENT; BAFETINIB; BOSUTINIB; DASATINIB; IMATINIB; NILOTINIB; PLACEBO; PONATINIB; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY;

ACUTE PANCREATITIS; ADVANCED CANCER; ADVERSE OUTCOME; AMYLASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CLINICAL EFFECTIVENESS; DISEASE COURSE; DISEASE SEVERITY; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; HUMAN; INOPERABLE CANCER; ISCHEMIA; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; PANCREAS DISEASE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

ACUTE DISEASE; AMYLASES; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; HUMANS; LIPASE; PANCREAS; PANCREATITIS; PATENTS AS TOPIC; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RISK ASSESSMENT; RISK FACTORS;

EID: 79954504859     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221311795399255     Document Type: Review

References (35)

1. Andrews, D., Barker, A.J., Finlay, M. R., Green, C., Jones, C. Imidazo[1,2-A]pyridine having anti-cell-proliferation activity. US7745428 (2010).
2. Badalov N, Baradarian R, Iswara K, Li J, Steinberg W, Tenner S. Drug-induced acute pancreatitis: An evidence-based review. Clin Gastroenterol Hepatol 2007; 5: 648-61.
3. Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: The M. D. Anderson experience. J Clin Endocrinol Metab 2010; 95(6): 2588-95.
4. Fyfe, G., Holmgren, E., Mass, R.D., Novotny, W. Treatment with anti-VEGF antibodies. US7622115 (2010).
5. Kang, I. C., Kim, E. Y., Choi Y. Screening method for epidermal growth factor receptor tyrosibe kinase inhibitor and inhibitors identified using same. WO2010107156 (2010).
6. Deininger MW, Vieira S, Mendiola R, Schultheis B, Goldman JM, Melo JV. BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. Cancer Res 2000; 60: 2049-55.
7. Jabbour E, Fava C, Kantarjian H. Advances in the biology and therapy of patients with chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009; 22: 395-407.
8. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23: 965-72.
9. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354: 2542-51.
10. Britten CD, Kabbinavar F, Hecht JR, Bello CL, Li J, Baum C, et al. A Phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol 2008; 61: 515-24.
11. Akaza H, Tsukamoto T, Murai M, Nakajima K, Naito S. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 2007; 37: 755-62.
12. Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 2008; 99: 159-65.
13. le Coutre P, Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCRABL tyrosine kinase inhibitor, is active in patients with imatinibresistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008; 111: 1834-9.
14. Hazarika M, Jiang X, Liu Q, Lee SL, Ramchandani R, Garnett C, et al. Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res 2008; 14: 5325-31.
15. Wörns MA, Weinmann A, Pfingst K, Schulte-Sasse C, Messow CM, Schulze-Bergkamen H, et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol 2009; 43: 489-95.
16. Medioni J, Choueiri TK, Zinzindohoué F, Cho D, Fournier L, Oudard S. Response of renal cell carcinoma pancreatic metastasis to sunitinib treatment: A retrospective analysis. J Urol 2009; 181: 2470-5.
17. Tojo A, Usuki K, Urabe A, Maeda Y, Kobayashi Y, Jinnai I, et al. A Phase I/II study of nilotinib in Japanese patients with imatinibresistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL. Int J Hematol 2009; 89: 679-88.
18. Zhou L, Meng F, Yin O, Wang J, Wang Y, Wei Y, et al. Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: A single- and multiple-dose, open-label pharmacokinetic study in Chinese patients. Clin Ther 2009; 31: 1568-75.
19. Rosti G, Palandri F, Castagnetti F, Breccia M, Levato L, Gugliotta G, et al. Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood 2009; 114: 4933-8.
20. Chi KH, Liao CS, Chang CC, Ko HL, Tsang YW, Yang KC, et al. Angiogenic blockade and radiotherapy in hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2010; 78(1): 188-93.
21. Beall, M., Huth, S. P., Krah, E. R. Antibodies that bind canine pancreatic lipase. US7722875 (2010).
22. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Cancer Therapy Evaluation Program (CTEP) 2006.
23. Pezzilli R, Corinaldesi R, Morselli-Labate AM. Tyrosine kinase inhibitors and acute pancreatitis. JOP 2010; 11: 291-3.
24. Bayer AG. Leverkusen, Germany. Nevaxar (sorafenib). Highlights of prescribing information.
25. Li M, Srinivas S. Acute pancreatitis associated with sorafenib. South Med J 2007; 100: 909-11.
26. Amar S, Wu KJ, Tan WW. Sorafenib-induced pancreatitis. Mayo Clin Proc 2007; 82: 521.
27. Saadati H, Saif MW. Sorafenib-induced acute pancreatitis. J Pancreas (Online) 2010; 11: 283-4.
28. Ueda T, Takeyama Y, Yasuda T, Matsumura N, Sawa H, Nakajima T, et al. Vascular endothelial growth factor increases in serum and protects against the organ injuries in severe acute pancreatitis. J Surg Res 2006; 134: 223-30.
29. Pierce GF, Mustoe TA, Lingelbach J, Masakowski VR, Griffin GL, Senior RM, et al. Platelet-derived growth factor and transforming growth factor-beta enhance tissue repair activities by unique mechanisms. J Cell Biol 1989; 109: 429-40.
30. McNiven, M.A., Singh, V.P. Treating pancreatitis. US20100160339 (2010).
31. Schnekenburger J, Mayerle J, Krüger B, Buchwalow I, Weiss FU, Albrecht E, et al. Protein tyrosine phosphatase kappa and SHP-1 are involved in the regulation of cell-cell contacts at adherens junctions in the exocrine pancreas. Gut 2005; 54: 1445-55.
32. Chong ZZ, Maiese K. The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: Diversified control of cell growth, inflammation, and injury. Histol Histopathol 2007; 22: 1251-67.
33. Sarmiento N, Sánchez-Bernal C, Ayra M, Pérez N, Hernández- Hernández A, Calvo JJ, et al. Changes in the expression and dynamics of SHP-1 and SHP-2 during cerulein-induced acute pancreatitis in rats. Biochim Biophys Acta 2008; 1782: 271-9.
34. de Dios I, Ramudo L, García-Montero AC, Manso MA. Redoxsensitive modulation of CD45 expression in pancreatic acinar cells during acute pancreatitis. J Pathol 2006; 210: 234-9.
35. Pezzilli R, Zerbi A, Di Carlo V, Bassi C, Delle Fave GF. Practical guidelines for acute pancreatitis. Pancreatology 2010; 10: 523-35.